Key Takeaways
- • F&C Investment Trust (FCIT) has reduced US equity exposure from 64.5% at end-2024 to 58.4% currently, citing valuation concerns and concentrated tech/AI concentration risks in concentrated portfolios.
- • Emerging markets allocation has more than doubled year-to-date, rising from 4.9% (end-2024) to 10.1% (end-August 2026), reflecting manager Paul Niven's pivot toward diversification amid "burgeoning fears of an overblown tech market."
- • The £6.4bn global equity trust has outperformed its FTSE All-World benchmark over 1, 3, 5, 10, and 20-year periods; shares rose 17.7% over the past year while trading at an 8% discount.
- • Manager Niven challenges the concentrated-stock thesis favored by peers, arguing that broad diversification ("buying the haystack") offers better odds of capturing winners than concentrated bets on identified leaders ("buying the needle").
- • The reallocation underscores institutional hesitance around US tech valuations and AI-driven equity concentration despite continued market strength, with NVIDIA remaining FCIT's largest holding.
Summary
F&C Investment Trust, London's oldest listed investment trust (established 1868), is systematically reducing exposure to US equities and reallocating capital to emerging markets as concerns mount over valuation excesses in concentrated technology and artificial intelligence stocks. The £6.4bn global equity trust has cut North American exposure to 58.4% of its portfolio, down from 64.5% at the end of 2024, while more than doubling emerging markets allocation to 10.1% from 4.9% over the same period.
Manager Paul Niven, who runs the trust through Columbia Threadneedle, acknowledged that FCIT benefited substantially from the rally in US equities and AI-linked stocks, noting particular strength from concentration in technology. However, he has begun easing this exposure in response to what he describes as unsustainable valuations in a narrow cohort of mega-cap tech and AI names. While NVIDIA remains the trust's largest holding, the directional shift reflects growing skepticism about whether concentrated portfolios—which many competitors argue can identify market winners—justify their risk profile relative to broad diversification strategies.
Niven frames the reallocation debate around a philosophical question: "Do you buy the haystack or do you buy the needle?" He argues that diversified portfolio construction offers superior long-term odds of capturing equity returns, particularly when only a small number of companies drive overall market performance in any given period. This positioning challenges the increasingly popular concentrated-stock approach adopted by many active managers, who contend they can isolate outperformers in technology and AI-driven sectors.
The trust's performance metrics support the diversification thesis: FCIT has outperformed its FTSE All-World benchmark over 1, 3, 5, 10, and 20-year periods. Shares appreciated 17.7% over the trailing 12 months and currently trade at an 8% discount to net asset value. The emerging markets pivot, occurring alongside broader market caution about AI valuations and warnings from senior banking executives about potential overvaluation in tech equities, positions FCIT to capture recovery dynamics in developing economies while reducing concentration risk in saturated US technology valuations.
Manager Paul Niven, who runs the trust through Columbia Threadneedle, acknowledged that FCIT benefited substantially from the rally in US equities and AI-linked stocks, noting particular strength from concentration in technology. However, he has begun easing this exposure in response to what he describes as unsustainable valuations in a narrow cohort of mega-cap tech and AI names. While NVIDIA remains the trust's largest holding, the directional shift reflects growing skepticism about whether concentrated portfolios—which many competitors argue can identify market winners—justify their risk profile relative to broad diversification strategies.
Niven frames the reallocation debate around a philosophical question: "Do you buy the haystack or do you buy the needle?" He argues that diversified portfolio construction offers superior long-term odds of capturing equity returns, particularly when only a small number of companies drive overall market performance in any given period. This positioning challenges the increasingly popular concentrated-stock approach adopted by many active managers, who contend they can isolate outperformers in technology and AI-driven sectors.
The trust's performance metrics support the diversification thesis: FCIT has outperformed its FTSE All-World benchmark over 1, 3, 5, 10, and 20-year periods. Shares appreciated 17.7% over the trailing 12 months and currently trade at an 8% discount to net asset value. The emerging markets pivot, occurring alongside broader market caution about AI valuations and warnings from senior banking executives about potential overvaluation in tech equities, positions FCIT to capture recovery dynamics in developing economies while reducing concentration risk in saturated US technology valuations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.